Homoarginine and cardiovascular outcome in the population-based dallas heart study

Dorothee Atzler, M. Odette Gore, Colby R. Ayers, Chi Un Choe, Rainer H. Böger, James A de Lemos, Darren K McGuire, Edzard Schwedhelm

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

Objective-The nonproteinogenic amino acid homoarginine has been postulated to have antiatherosclerotic effects as a weak substrate of nitric oxide synthase. This investigation in the population-based Dallas Heart Study (DHS) aimed to evaluate the association of homoarginine with clinical and subclinical cardiovascular outcomes.

Approach and Results-Plasma homoarginine was measured in 3514 participants of the DHS using liquid chromatographytandem mass spectrometry. Associations between homoarginine and major adverse cardiovascular events and all-cause mortality were analyzed using Cox proportional hazard models adjusting for cardiovascular risk factors. Linear regression was used to assess cross-sectional associations between homoarginine and subclinical cardiovascular disease, including coronary artery calcium measured by electron beam-computed tomography, and aortic plaque burden and aortic wall thickness by MRI. Median age was 43 (interquartile range, 36-52) years, with 56% women and 52% black participants. Median follow-up was 9.4 (9.0-9.8) years. Median plasma homoarginine was 2.80 (2.14-3.54) ìmol/L. In multivariable models, higher homoarginine was associated with lower rate of major adverse cardiovascular events (hazard ratio, 0.86; 95% confidence interval, 0.75-0.98) and lower all-cause mortality (hazard ratio, 0.82; 0.73-0.92; per 1 log SD increase in homoarginine). Homoarginine was inversely and independently associated with aortic wall thickness (β-estimate, .0.04; P<0.01) but not with aortic plaque burden and coronary artery calcium.

Conclusions-Homoarginine is inversely associated with subclinical vascular disease and with risk for cardiovascular disease events. Additional studies are needed to evaluate whether the regulation of plasma homoarginine could emerge as a novel therapeutic option to improve outcomes in cardiovascular disease.

Original languageEnglish (US)
Pages (from-to)2501-2507
Number of pages7
JournalArteriosclerosis, Thrombosis, and Vascular Biology
Volume34
Issue number11
DOIs
StatePublished - Nov 1 2014

Fingerprint

Homoarginine
Population
Cardiovascular Diseases
Coronary Vessels
Calcium
X Ray Computed Tomography
Mortality
Vascular Diseases
Proportional Hazards Models
Nitric Oxide Synthase

Keywords

  • Atherosclerosis
  • Epidemiology
  • Nitric oxide

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Medicine(all)

Cite this

Homoarginine and cardiovascular outcome in the population-based dallas heart study. / Atzler, Dorothee; Gore, M. Odette; Ayers, Colby R.; Choe, Chi Un; Böger, Rainer H.; de Lemos, James A; McGuire, Darren K; Schwedhelm, Edzard.

In: Arteriosclerosis, Thrombosis, and Vascular Biology, Vol. 34, No. 11, 01.11.2014, p. 2501-2507.

Research output: Contribution to journalArticle

Atzler, Dorothee ; Gore, M. Odette ; Ayers, Colby R. ; Choe, Chi Un ; Böger, Rainer H. ; de Lemos, James A ; McGuire, Darren K ; Schwedhelm, Edzard. / Homoarginine and cardiovascular outcome in the population-based dallas heart study. In: Arteriosclerosis, Thrombosis, and Vascular Biology. 2014 ; Vol. 34, No. 11. pp. 2501-2507.
@article{53c74de61e474041afd7216610b9d3ea,
title = "Homoarginine and cardiovascular outcome in the population-based dallas heart study",
abstract = "Objective-The nonproteinogenic amino acid homoarginine has been postulated to have antiatherosclerotic effects as a weak substrate of nitric oxide synthase. This investigation in the population-based Dallas Heart Study (DHS) aimed to evaluate the association of homoarginine with clinical and subclinical cardiovascular outcomes.Approach and Results-Plasma homoarginine was measured in 3514 participants of the DHS using liquid chromatographytandem mass spectrometry. Associations between homoarginine and major adverse cardiovascular events and all-cause mortality were analyzed using Cox proportional hazard models adjusting for cardiovascular risk factors. Linear regression was used to assess cross-sectional associations between homoarginine and subclinical cardiovascular disease, including coronary artery calcium measured by electron beam-computed tomography, and aortic plaque burden and aortic wall thickness by MRI. Median age was 43 (interquartile range, 36-52) years, with 56{\%} women and 52{\%} black participants. Median follow-up was 9.4 (9.0-9.8) years. Median plasma homoarginine was 2.80 (2.14-3.54) {\`i}mol/L. In multivariable models, higher homoarginine was associated with lower rate of major adverse cardiovascular events (hazard ratio, 0.86; 95{\%} confidence interval, 0.75-0.98) and lower all-cause mortality (hazard ratio, 0.82; 0.73-0.92; per 1 log SD increase in homoarginine). Homoarginine was inversely and independently associated with aortic wall thickness (β-estimate, .0.04; P<0.01) but not with aortic plaque burden and coronary artery calcium.Conclusions-Homoarginine is inversely associated with subclinical vascular disease and with risk for cardiovascular disease events. Additional studies are needed to evaluate whether the regulation of plasma homoarginine could emerge as a novel therapeutic option to improve outcomes in cardiovascular disease.",
keywords = "Atherosclerosis, Epidemiology, Nitric oxide",
author = "Dorothee Atzler and Gore, {M. Odette} and Ayers, {Colby R.} and Choe, {Chi Un} and B{\"o}ger, {Rainer H.} and {de Lemos}, {James A} and McGuire, {Darren K} and Edzard Schwedhelm",
year = "2014",
month = "11",
day = "1",
doi = "10.1161/ATVBAHA.114.304398",
language = "English (US)",
volume = "34",
pages = "2501--2507",
journal = "Arteriosclerosis, Thrombosis, and Vascular Biology",
issn = "1079-5642",
publisher = "Lippincott Williams and Wilkins",
number = "11",

}

TY - JOUR

T1 - Homoarginine and cardiovascular outcome in the population-based dallas heart study

AU - Atzler, Dorothee

AU - Gore, M. Odette

AU - Ayers, Colby R.

AU - Choe, Chi Un

AU - Böger, Rainer H.

AU - de Lemos, James A

AU - McGuire, Darren K

AU - Schwedhelm, Edzard

PY - 2014/11/1

Y1 - 2014/11/1

N2 - Objective-The nonproteinogenic amino acid homoarginine has been postulated to have antiatherosclerotic effects as a weak substrate of nitric oxide synthase. This investigation in the population-based Dallas Heart Study (DHS) aimed to evaluate the association of homoarginine with clinical and subclinical cardiovascular outcomes.Approach and Results-Plasma homoarginine was measured in 3514 participants of the DHS using liquid chromatographytandem mass spectrometry. Associations between homoarginine and major adverse cardiovascular events and all-cause mortality were analyzed using Cox proportional hazard models adjusting for cardiovascular risk factors. Linear regression was used to assess cross-sectional associations between homoarginine and subclinical cardiovascular disease, including coronary artery calcium measured by electron beam-computed tomography, and aortic plaque burden and aortic wall thickness by MRI. Median age was 43 (interquartile range, 36-52) years, with 56% women and 52% black participants. Median follow-up was 9.4 (9.0-9.8) years. Median plasma homoarginine was 2.80 (2.14-3.54) ìmol/L. In multivariable models, higher homoarginine was associated with lower rate of major adverse cardiovascular events (hazard ratio, 0.86; 95% confidence interval, 0.75-0.98) and lower all-cause mortality (hazard ratio, 0.82; 0.73-0.92; per 1 log SD increase in homoarginine). Homoarginine was inversely and independently associated with aortic wall thickness (β-estimate, .0.04; P<0.01) but not with aortic plaque burden and coronary artery calcium.Conclusions-Homoarginine is inversely associated with subclinical vascular disease and with risk for cardiovascular disease events. Additional studies are needed to evaluate whether the regulation of plasma homoarginine could emerge as a novel therapeutic option to improve outcomes in cardiovascular disease.

AB - Objective-The nonproteinogenic amino acid homoarginine has been postulated to have antiatherosclerotic effects as a weak substrate of nitric oxide synthase. This investigation in the population-based Dallas Heart Study (DHS) aimed to evaluate the association of homoarginine with clinical and subclinical cardiovascular outcomes.Approach and Results-Plasma homoarginine was measured in 3514 participants of the DHS using liquid chromatographytandem mass spectrometry. Associations between homoarginine and major adverse cardiovascular events and all-cause mortality were analyzed using Cox proportional hazard models adjusting for cardiovascular risk factors. Linear regression was used to assess cross-sectional associations between homoarginine and subclinical cardiovascular disease, including coronary artery calcium measured by electron beam-computed tomography, and aortic plaque burden and aortic wall thickness by MRI. Median age was 43 (interquartile range, 36-52) years, with 56% women and 52% black participants. Median follow-up was 9.4 (9.0-9.8) years. Median plasma homoarginine was 2.80 (2.14-3.54) ìmol/L. In multivariable models, higher homoarginine was associated with lower rate of major adverse cardiovascular events (hazard ratio, 0.86; 95% confidence interval, 0.75-0.98) and lower all-cause mortality (hazard ratio, 0.82; 0.73-0.92; per 1 log SD increase in homoarginine). Homoarginine was inversely and independently associated with aortic wall thickness (β-estimate, .0.04; P<0.01) but not with aortic plaque burden and coronary artery calcium.Conclusions-Homoarginine is inversely associated with subclinical vascular disease and with risk for cardiovascular disease events. Additional studies are needed to evaluate whether the regulation of plasma homoarginine could emerge as a novel therapeutic option to improve outcomes in cardiovascular disease.

KW - Atherosclerosis

KW - Epidemiology

KW - Nitric oxide

UR - http://www.scopus.com/inward/record.url?scp=84911869613&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84911869613&partnerID=8YFLogxK

U2 - 10.1161/ATVBAHA.114.304398

DO - 10.1161/ATVBAHA.114.304398

M3 - Article

C2 - 25189571

AN - SCOPUS:84911869613

VL - 34

SP - 2501

EP - 2507

JO - Arteriosclerosis, Thrombosis, and Vascular Biology

JF - Arteriosclerosis, Thrombosis, and Vascular Biology

SN - 1079-5642

IS - 11

ER -